Radiobiology of Radiosurgery and Radioablation: Beyond the “5 Rs” - Presented by: Minesh Mehta, M.D.
Please login or register to take this course.
- Analyze and discuss recommendations from evidence-based literature reviews.
- Implement practical principles demonstrating key pragmatic takeaway pearls.
- Discuss practical tips, interesting cases and workflow improvements in the practice of radiosurgery.
FACULTY AND DISCLOSURES:
Minesh P. Mehta, M.D.
Deputy Director and Chief of Radiation Oncology, Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida
Chair and Professor, Department of Radiation Oncology
Herbert Wertheim College of Medicine, Florida International University
Minesh P. Mehta, M.D., FASTRO, is on the Board of Directors for Oncoceutics, serves on the Medical Advisory Board for Mevion and is a consultant for Karyopharm, Sapience and Xoft and is a stock/share holder with Chimerix.
Michael McDermott, M.D.
Michael McDermott, M.D., faculty for this educational event, is a consultant with Deinde Medical and Stryker, and has indicated that the presentations or discussions will not include off-label or unapproved product usage.
All of the relevant financial relationships listed for this/these individuals has/have been mitigated.
Rupesh Kotecha, M.D.
Rupesh Kotecha, M.D., faculty for this educational event, has received an honoraria from Elekta AB, Accuray Inc., Viewray Inc., Novocure Inc., and Elseivier. He has received research support from Medtronic, B. Earth Diagnostics, Novocure, Exelixis, CT Medical, Astrazeneca and Viewray. He is also on the speakers bureau with Novocure and has indicated that the presentation(s) or discussion(s) will not include off-label or unapproved product usage.
All of the relevant financial relationships listed for this/these individual(s) has/have been mitigated.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*
*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.